A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker.

Iakovos Toumazis S Ayca Erdogan Mehrad BastaniAnn LeungSylvia K Plevritis

Published in: JNCI cancer spectrum (2021)

Lung cancer screening that incorporates a diagnostic biomarker, in place of Lung-RADS 3 and 4A guidelines, could improve the cost-effectiveness of the screening program and warrants further investigation.

Keyphrases

low dose
computed tomography
magnetic resonance imaging
high dose
positron emission tomography
quality improvement
pet ct
contrast enhanced ultrasound